Rodríguez Piñas, José MaríaRomero Lorca, AliciaGaibar Alonso, MaríaNovillo Villajos, ApoloniaRubio Alonso, MargaritaMalón, DiegoAntón Pascual, BeatrizCamacho Castañeda, Francisca InmaculadaCavanagh, MercedesFernández Santander, AnaEt. al.2026-06-102026-06-102025Rodríguez-Piñas, J. M., Romero-Lorca, A., Gaibar, M., Novillo, A., Rubio, M., Malón, D., Antón-Pascual, B., Camacho, F. I., Cavanagh, M., Luján, D. R., Martín, A. M., Khedaoui, R., Moreno, D., Pinedo, F., Boiza, M., García-Adrián, S., Gómez, P., Marrupe, D., & Fernández-Santander, A. (2025). Tumour snps associated with immune-related hepatitis in patients with melanoma receiving immune checkpoint inhibitors. Biomedicines, 13(10), 2351. https://doi.org/10.3390/biomedicines131023512227-9059https://hdl.handle.net/11268/17154Immune checkpoint inhibitors (ICIs) have significantly improved survival rates for patients with metastatic melanoma. However, these treatments can lead to immune-related adverse events (irAEs), including hepatitis. This exploratory study sought to identify tumour single-nucleotide polymorphisms (SNPs) associated with the risk of ICI-induced hepatitis in melanoma patients.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/MedicinaMelanomaBiomarcadoresHepatitisjournal article10.3390/biomedicines13102351open accessCáncerPatologíaInmunologíaGoal 3: Ensure healthy lives and promote well-being for all at all ages